| 000 | 01234 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250512074825.0 | ||
| 264 | 0 | _c19860310 | |
| 008 | 198603s 0 0 eng d | ||
| 022 | _a0379-0363 | ||
| 024 | 7 |
_a10.1007/978-3-0348-7720-6_19 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMcGill, P E | |
| 245 | 0 | 0 |
_aNSAID-plasma concentration monitoring--optimizing treatment of R.A. _h[electronic resource] |
| 260 |
_bAgents and actions. Supplements _c1985 |
||
| 300 |
_a157-61 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIbuprofen _xadministration & dosage |
| 650 | 0 | 4 |
_aIndomethacin _xadministration & dosage |
| 650 | 0 | 4 | _aKinetics |
| 650 | 0 | 4 | _aMetabolic Clearance Rate |
| 650 | 0 | 4 |
_aNaproxen _xadministration & dosage |
| 650 | 0 | 4 |
_aPhenylacetates _xadministration & dosage |
| 650 | 0 | 4 |
_aPhenylbutazone _xadministration & dosage |
| 773 | 0 |
_tAgents and actions. Supplements _gvol. 17 _gp. 157-61 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/978-3-0348-7720-6_19 _zAvailable from publisher's website |
| 999 |
_c3872965 _d3872965 |
||